Pharmaceutical patent analyst最新文献

筛选
英文 中文
Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market. 药品专利及其对药品获取的影响:以撒哈拉以南非洲市场为重点。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-09-01 Epub Date: 2022-09-30 DOI: 10.4155/ppa-2022-0044
Shemaiah O Okeniyi, Melody Okereke
{"title":"Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market.","authors":"Shemaiah O Okeniyi, Melody Okereke","doi":"10.4155/ppa-2022-0044","DOIUrl":"https://doi.org/10.4155/ppa-2022-0044","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ever-expanding landscape: Alzheimer's - new targets and new patents. 不断扩张的版图:阿尔茨海默病——新的目标和新的专利。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-09-01 Epub Date: 2022-09-02 DOI: 10.4155/ppa-2022-0031
Ayodeji O Egunlusi, Jacques Joubert
{"title":"Ever-expanding landscape: Alzheimer's - new targets and new patents.","authors":"Ayodeji O Egunlusi, Jacques Joubert","doi":"10.4155/ppa-2022-0031","DOIUrl":"https://doi.org/10.4155/ppa-2022-0031","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40344699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer. 高度稳定、无毒、功能化的纳米乳,用于癌症的早期诊断和改善。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-09-01 Epub Date: 2022-10-06 DOI: 10.4155/ppa-2021-0029
Ramesh Joga, Christy J Pulini-Kunnel, Chetan D Sabanis, Simran, Sandeep Kumar, Neeraj Kumar
{"title":"Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer.","authors":"Ramesh Joga,&nbsp;Christy J Pulini-Kunnel,&nbsp;Chetan D Sabanis,&nbsp;Simran,&nbsp;Sandeep Kumar,&nbsp;Neeraj Kumar","doi":"10.4155/ppa-2021-0029","DOIUrl":"https://doi.org/10.4155/ppa-2021-0029","url":null,"abstract":"<p><p><b>Aim:</b> To overcome the limitations associated with conventional formulations for cancer treatment by the effective utilization of nanoemulsion with therapy and diagnosis through the single unit. <b>Patent:</b> US20210275687 describes the usage of functionalized various oil-in-water nanoemulsions as pharmacological vehicles with theranostic potential in cancer treatment. <b>Materials & methods:</b> Vitamin E, oleic acid, sphingomyelin, ligands for functionalization, contrast agents and therapeutic biomolecules. <b>Results:</b> The toxicity studies conducted on healthy mice did not show any apparent toxicity issues. The stability studies conducted at 40 °C and 75% relative humidity, which is mandatory for regulatory approval, indicated the adequate physical stability of the formulation. <b>Conclusion:</b> The studies exhibited the promising theranostic potential of the developed nanoemulsion for the effective management and diagnosis of cancer and metastatic diseases.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33490176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Oxaliplatin-flavone pharmaceutical co-crystal-CN111205332A: patent spotlight. 奥沙利铂-黄酮类药物共晶cn111205332a:专利聚光灯。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-09-01 Epub Date: 2022-09-02 DOI: 10.4155/ppa-2022-0011
Ritu Rathi, Renu Kushwaha, Ayushi Goyal, Inderbir Singh
{"title":"Oxaliplatin-flavone pharmaceutical co-crystal-CN111205332A: patent spotlight.","authors":"Ritu Rathi,&nbsp;Renu Kushwaha,&nbsp;Ayushi Goyal,&nbsp;Inderbir Singh","doi":"10.4155/ppa-2022-0011","DOIUrl":"https://doi.org/10.4155/ppa-2022-0011","url":null,"abstract":"<p><p>Co-crystallization is a technique for modifying physicochemical properties of pharmaceutical ingredients with an aim to enhance the therapeutic efficacy and subsequent reduction in toxicity. The patent describes the development of oxaliplatin co-crystals using flavonoids (baicalein and naringenin) via solvent volatilization technique with an objective to improve solubility and stability in GI tract and reduced side/toxic effects. The co-crystals were characterized via differential scanning calorimetry, thermogravimetric analysis, x-ray diffraction analysis. The co-crystals exhibited slow drug release, delayed hydrolysis, low cytotoxicity and enhanced therapeutic activity on human gastric adenocarcinoma cells. However, suitable solvent for co-crystal production, large scale production and regulatory challenges for continuous manufacturing of co-crystals must be addressed.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40341256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights February-March 2022. 专利亮点:2022年2月至3月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-07-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0013
Hermann Am Mucke
{"title":"Patent highlights February-March 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0013","DOIUrl":"https://doi.org/10.4155/ppa-2022-0013","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40634287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Six drugs facing key patent expirations and potential generic entry from May to June 2022. 2022年5月至6月,6种药物面临关键专利到期和潜在仿制药上市。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-07-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0018
Yali Friedman
{"title":"Six drugs facing key patent expirations and potential generic entry from May to June 2022.","authors":"Yali Friedman","doi":"10.4155/ppa-2022-0018","DOIUrl":"https://doi.org/10.4155/ppa-2022-0018","url":null,"abstract":"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent update on drug patent linkage system in China. 中国药品专利联动制度最新进展。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-06-14 DOI: 10.4155/ppa-2022-0012
Weiwei Han
{"title":"Recent update on drug patent linkage system in China.","authors":"Weiwei Han","doi":"10.4155/ppa-2022-0012","DOIUrl":"https://doi.org/10.4155/ppa-2022-0012","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42932865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry. 瑞德西韦:新冠肺炎治疗的专利趋势、临床证据、药理学和化学综述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-05-31 DOI: 10.4155/ppa-2021-0023
Sandro G Viveiros Rosa, W. C. Santos
{"title":"Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry.","authors":"Sandro G Viveiros Rosa, W. C. Santos","doi":"10.4155/ppa-2021-0023","DOIUrl":"https://doi.org/10.4155/ppa-2021-0023","url":null,"abstract":"By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44349785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patent highlights October-November 2021. 专利亮点2021年10月至11月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-05-31 DOI: 10.4155/ppa-2022-0003
H. Mucke
{"title":"Patent highlights October-November 2021.","authors":"H. Mucke","doi":"10.4155/ppa-2022-0003","DOIUrl":"https://doi.org/10.4155/ppa-2022-0003","url":null,"abstract":"A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45317231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights December 2021-January 2022. 专利亮点2021年12月至2022年1月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-05-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0006
Hermann Am Mucke
{"title":"Patent highlights December 2021-January 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0006","DOIUrl":"https://doi.org/10.4155/ppa-2022-0006","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40612852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信